Feasibility and performance of catheter ablation with zero-fluoroscopy approach for regular supraventricular tachycardia in patients with structural and/or congenital heart disease

Aleksandra Morka, MD, PhD\textsuperscript{a,*}, Janusz Śledź, MD, PhD\textsuperscript{b}, Karol Deutsch, MD\textsuperscript{b}, Bartosz Ludwik, MD\textsuperscript{c}, Magdalena Zagrodzka, MD, PhD\textsuperscript{d}, Lesław Szydłowski, MD, PhD\textsuperscript{e}, Sebastian Stec, MD, PhD\textsuperscript{f}

Abstract
Patients with structural heart disease (SHD) are more difficult to ablate than those with a structurally healthy heart. The reason may be technical problems. We compared periprocedural data in unselected patients (including SHD group) recruited for zero-fluoroscopy catheter ablation (ZF-CA) of supraventricular arrhythmias (SVTs). Consecutive adult patients with atrioventricular nodal reentry tachycardia (AVNRT), accessory pathways (AP), atrial flutter (AFL), and atrial tachycardia (AT) were recruited. A 3-dimensional electroanatomical mapping system (Ensite Velocity, NavX, St Jude Medical, Lake Bluff, Illinois) was used to create electroanatomical maps and navigate catheters. Fluoroscopy was used on the decision of the first operator after 5 minutes of unresolved problems.

Of the 1280 patients ablated with the intention to be treated with ZF approach, 174 (13.6%) patients with SHD (age: 58.2 ± 13.6; AVNRT: 23.9%; AP: 8.5%; AFL: 61.4%; and AT: 6.2%) were recruited. These patients were compared with the 1106 patients with nonstructural heart disease (NSHD) (age: 51.4 ± 16.4; AVNRT: 58.0%; AP: 17.6%; AFL: 20.7%; and AT: 3.7%; P < 0.001). Procedural time (49.9 ± 24.6 vs 49.1 ± 23.9 minutes, \( P = 0.55 \)) and number of applications were similar between groups (\( P = 0.08 \)). The rate of conversion from ZF-CA to fluoroscopy was slightly higher in SHD as compared to NSHD (13.2% vs 7.8%, \( P = 0.02 \)) while the total time of fluoroscopy and radiation doses were comparable in the group of SHD and NSHD (\( P = 0.55 \), \( P = 0.48 \)).

ZF-CA is feasible and safe in majority of patients with SHD and should be incorporated into a standard approach for SHD; however, the procedure requires sufficient experience.

Abbreviations: AFL = atrial flutter, AVNRT = atrioventricular nodal reentry tachycardia, CS = coronary sinus, EPS = electrophysiology study, GUCH = grown-up congenital disease, NSHD = nonstructural heart defects or disease, SHD = structural heart defects or diseases, SVT = supraventricular tachycardia, ZF-CA = zero-fluoroscopy catheter ablation.

Keywords: adult congenital heart disease, radiation exposure, radiofrequency catheter ablation, structural heart disease, supraventricular tachyarrhythmia

1. Introduction
Significant progress has been made in percutaneous catheter ablation (CA) for supraventricular arrhythmias (SVTs) over the last 3 decades, with significant reductions in complications and improvements in efficacy.\textsuperscript{1–13} However, the use of fluoroscopy for catheter navigation and monitoring during most intervention  

with cumulative exposure. Reducing or eliminating exposure is highly recommended for patients in several cases, such as pregnancy, young age, cancer, skin disorders, and obesity, and for those undergoing repetitive procedures especially for cardiac, cardiothoracic, or vertebral column anomalies.

Considerable development has been made given that 3D-electroanatomical mapping (3D-EAM) systems have been implemented that precisely enable the creation of a 3D cardiac anatomy and the real-time navigation of catheters without the need of fluoroscopy.

In recent years, many scientific studies have been published on the experience of implementing procedures with significantly reduced fluoroscopy (near-ZF) or zero-fluoroscopy (ZF) approach.

The literature reviews so far indicate that most authors report their experience with ZF in patients without a structural heart disease (SHD). Patients with any SHD, including subgroups, that is: organic heart diseases; ischemic/nonischemic dilated cardiomyopathy and other cardiomyopathies; anatomical defects; grown-up congenital heart disease or adult congenital heart disease (GUCH/ACHD); and hypertrophic cardiomyopathy, and those with previous cardiac surgery for valvular heart disease or past coronary artery bypass grafting or severe thoracic anomalies seem to pose a real challenge for electrophysiologists.

Moreover, in some of randomized trials on ZF or near-ZF approach, patients with abovementioned conditions were routinely excluded.

The purpose of this study was compared periprocedural data in consecutive patients recruited from a prospective registry including cases of ZF for CA of SVTs. Further, periprocedural data of patients with SHDs were compared with those of patients with nonstructural heart diseases (NSHDs).

### 2. Patients and methods

Data were obtained from a prospective standardized multicenter CA registry from January 2012 to February 2017. Seven centers were included. In all, 1280 consecutive unselected adult patients (mean age, 52.3 ± 16.2 years) with a final diagnosis of SVT or supraventricular substrate were recruited. The conditions included atrioventricular nodal reentry tachycardia (AVNRT), accessory pathway, atrial flutter (AFL), and atrial tachycardia. The only contraindications for ZF were cardiac implantable electronic devices, planned pulmonary vein isolation (PVI) procedure, and post-PVI arrhythmias. SHD was not the primary contraindication for following the ZF approach. The data of 174 patients with SHD were compared with those of patients with nonstructural heart diseases (NSHDs).

#### 2.1. Standard electrophysioloogy study (EPS) and zero-fluoroscopy catheter ablation (ZF-CA) approach

The protocols for the simplified approach and ZF have been reported earlier. The simplified 2-catheter femoral approach included the following: the use of 2 catheters, an ablation catheter, and a nonsteerable decapolar diagnostic catheter (APT Medical Inc., Shenzhen, China, St. Jude Medical, St. Paul, MN or Biotronik, Berlin, Germany); standardized catheter positioning during the procedure (decapolar catheter in the coronary sinus [CS] and mapping/ablation catheter in the right atrium, His region, and right ventricle); and standardized ventricular and atrial EPS before and after ablation with a 10 to 15-minute observation period. If CS cannulation was not achieved within 5 minutes, the decapolar catheter was positioned on the lateral site of the tricuspid annulus or in the superior vena cava. An electrophysiological recording system (EP-Tracer, Cardio-Tek, Maastricht, The Netherlands) was used during procedures with standard filters. Standard settings (max. 60–65°C and 50 [in AVNRT]–65 W [in AFL]) of the RF generator (Stockert, Biosense-Webster, Diamond Bar, CA) were used. Mapping was performed by creating a simplified map with the 3D-EAM system (Ensite Velocity NavX, St. Jude Medical, Lake Bluff, Illinois). The 3D map was projected at 30° left anterior oblique and 30° right anterior oblique positions.

If the arrhythmia originated from the left atrium or mitral annulus, the ablation catheter was inserted through the patent foramen ovale or retrogradely via the femoral artery.

By definition, the ZF approach was followed as an intention-to-perform procedure; therefore, the medical staff was not using lead-protective aprons until fluoroscopy was needed. If necessary, the fluoroscopy was performed, and the decision was made by the main operator after 5 minutes of unresolved navigational issues observed via catheter monitoring, for safety reasons or the need for a transseptal puncture. No intracardiac echocardiography was available in this group. A clear explanation concerning the reasons for using fluoroscopy was prespecified in the computer database and registry protocol, and this should be written in the medical reports and stored in the database. The procedural...
definitions, end-points, and complications were based on standard clinical definition. Patient status was reported in the medical reports and stored in the database immediately after ablation, after 1 day, and before hospital discharge. Only in-hospital complications were recorded.

2.2. Data collection

All preoperational data were collected prospectively in a computer database and saved. The data were also collected during ablation and supplemented with the results of treatment.

2.3. Statistical analysis

The data of patients with SHD were compared with those of patients with NSHD. All results were subjected to a statistical analysis. Data were presented as mean (SD) and percentages (%). The Student t test was used to compare differences between groups. All analyses were made using the licensed Statistica 13.1 package. All tests were statistically significant when “P” was <.05.

3. Results

The study population consisted of 1280 consecutive patients with SVT; of which, 174 patients had SHD. The baseline characteristics of the study groups are presented in Table 1.

On studying the scores for clinical symptoms, we noted that SHD patients presented with significantly higher exercise intolerance (P < .001) and more frequent palpitations (P = .008) than NSHD patients, while other symptom intensities (such as those for dyspnea, chest pain, and dizziness) were similar in both groups (P > .05). Moreover, the incidence for syncope was similar. SHD patients had significantly worse heart failure parameters than NSHD patients (P < .001).

A detailed analysis of 174 SHD patients (Table 2) showed that the organic heart diseases group was most commonly studied (58.6%) and consisted of patients with various types of cardiomyopathies, mitral or aortic valve anomalies, aortic aneurysms, Ebstein anomaly, or dextroversion and patients who had previously undergone percutaneous coronary interventions due to acute coronary syndromes. The next group was of postsurgery patients (17.8%) including those who had undergone coronary artery bypass grafting and mitral or aortic valvuloplasty (or replacement). Another group consisted of patients with significant thorax anomalies (13.7%), and the last group comprised GUCH patients (9.7%). In this group, there were individuals after atrial septal defect (ASD 2) and ventricular septal defect (VSD) closure. Some of the patients had at least 2 or more SHDs but the most advanced type was considered during classification.

Analysis of different types of SVT suggested that in SHD patients, AFL (61.3%) was the most common, while in NSHD patients, AVNRT (57.7%) was the most common. In both groups, atrial tachycardia was the least likely to be observed. Only in NSHD group frequent symptomatic premature ventricular contraction/ventricular tachycardia (1.3%) were additionally ablated during the same session. The remaining results are shown in Table 3.

Next, several basic parameters during EPS and ablation in SHD and NSHD patients were compared (Table 4). Procedural time was similar between patients with SHD and NSHD (49.9 ± 24.6 vs 49.1 ± 23.9 minutes, P = .55).

The rate of conversion from 2F-CA to fluoroscopy and failed procedure were slightly higher in SHD as compared to NSHD (13.2% vs 7.8% P = .02). The number of applications as well as total procedural time for CA, total time of fluoroscopy, and radiation exposure were similar in both groups, and differences

### Table 1

**General characteristic patients with structural heart disease and nonstructural heart disease.**

|                         | Total cohort n = 1280 | SHD n = 174 | NSHD n = 1106 | P value |
|-------------------------|-----------------------|-------------|---------------|---------|
| General characteristics  |                       |             |               |         |
| Mean age, yr            | 52.3 ± 16.2           | 58.2 ± 13.6 | 51.4 ± 16.4   | <.001   |
| Range                   | (18–91)               | (18–88)     | (18–91)       |         |
| Height, cm              | 169.2 ± 8.8           | 171.7 ± 11.8| 168.9 ± 10.9  | <.001   |
| Range                   | (149–200)             | (149–197)   | (149–200)     |         |
| Weight, kg              | 77.9 ± 16.7           | 84.8 ± 18.7 | 76.9 ± 16.1   | <.001   |
| Range                   | (34–155)              | (34–155)    | (34–155)      |         |
| BMI                     | 28.2 ± 5.8            | 26.0 ± 5.4  | 26.0 ± 5.4    | <.001   |
| Male patients           | 901 (45.3%)           | 118 (70.2%) | 473 (41.6%)   | <.001   |
| Basic clinical symptoms (score 1–10) |               |             |               |         |
| Exercise intolerance    | 5.3 ± 3.8             | 6.1 ± 3.8   | 5.1 ± 3.9     | <.001   |
| Dyspnea                 | 4.5 ± 3.1             | 4.7 ± 3.1   | 4.5 ± 3.2     | .31     |
| Chest pain              | 1.6 ± 2.0             | 1.7 ± 3.1   | 1.6 ± 2.9     | .54     |
| Palpitations            | 7.3 ± 3.8             | 6.6 ± 4.0   | 7.4 ± 3.8     | .01     |
| Fatigue                 | 3.7 ± 3.8             | 4.0 ± 4.0   | 3.6 ± 3.8     | .16     |
| Dizziness               | 3.8 ± 3.2             | 3.9 ± 3.3   | 3.8 ± 3.2     | .59     |
| Preyncope               | 3.3 ± 3.2             | 3.2 ± 3.2   | 3.3 ± 3.3     | .76     |
| Syncope                 | 0.7 ± 2.1             | 0.5 ± 1.8   | 0.7 ± 2.1     | .34     |
| Echocardiographic findings |                   |             |               |         |
| EF, %                   | 60.6 ± 8.9            | 48.9 ± 13.2 | 62.7 ± 5.7    | <.001   |
| LVDD, mm                | 48.9 ± 6.1            | 53.3 ± 7.6  | 48.2 ± 5.5    | <.001   |
| LVDS, mm                | 32.3 ± 6.4            | 38.1 ± 8.8  | 31.2 ± 5.3    | <.001   |
| LA, mm                  | 38.2 ± 6.8            | 42.5 ± 6.9  | 37.3 ± 6.4    | <.001   |

BM = body mass index, EF = ejection fraction, LA = left atrium, LVDD = left ventricle diameter in diastole, LVDS = left ventricle diameter in systole, NSHD = nonstructural heart disease, SHD = structural heart disease.
were not statistically significant (P > .05). However, there were significantly higher values in the SHD patients with regard to the duration of measurement and maximum values for energy and temperature in RF settings. This difference may be associated with differences in ablated substrates because in AFI, higher energy settings were required. The study showed that the minimally invasive ZF approach without the use of intracardiac echocardiography (ICE) enabled treatment without fluoroscopy in majority of patients (> 90%) with a short treatment duration and very high safety profile, comparable to that reported in previous meta-analysis. Moreover, the study reports information on differences in CA of SVT between SHD and NSHD.

SHD patients and medical staff are usually exposed to radiation several times in the current medical settings. Therefore, efforts to minimize the risk of irradiation should be validated while developing technologies (eg, 3D-EAM systems) and progressing in electrophysiology. There are several additional techniques and devices that facilitate the use of ZF approach during electrophysiological procedures (ICE, TEE, Carto UNIVU, contact force, imaging integration, and MediGuide). However, their additional costs and complexity of management should be taken into account for universal use of these approaches in EP lab worldwide.

We have been applying the ZF approach during ablation for several years. In this study, we present an analysis of a large group of patients with SHD including adolescent GUCH/AHCH patients in whom ablation was performed without the use of fluoroscopy. Other authors are also increasingly reducing the use of fluoroscopy for ablation; however, SHD is rare and the incidence of SHD is low in their described groups.

### Table 2

| Primary SHD | n=174 | (100%) |
|-------------|-------|--------|
| OHD | 102 (58.6) |
| MV and AoV anomaly | 32 |
| PCI | 25 |
| HGM | 14 |
| CMP dilated | 12 |
| RVH (Ph) | 6 |
| CMP tachysystolic | 6 |
| Al aneurysm | 3 |
| Ebstein anomaly | 2 |
| NCC | 1 |
| Dextroversion | 1 |
| Postsurgery | 31 (17.8) |
| CABG | 20 |
| Aof repl. | 8 |
| MV plasty | 3 |
| TA | 24 (13.8) |
| ACHD/GUCH | 17 (9.8) |
| ASD 2: surgery | 12 |
| ASD 2: Amplatz Septal Occluder | 3 |
| ASD 2 & PAPVR | 1 |
| VSD: surgery | 1 |

AHD = adult congenital heart disease, AoV repl. = aortic valve replacement, ASD = 2-ostium secundum atrial septal defect, CABG = coronary artery bypass grafting, CMP = cardiomyopathy, GUCH = grown-up congenital heart disease, HGM = hypertrophic cardiomyopathy, MV plasty = mitral valve repair and mitral valve replacement, NCC = noncompaction cardiomyopathy, OHD = organic heart disease, PACVR = partial anomalous pulmonary venous return, PCI = percutaneous coronary intervention, RVH = right ventricular hypertrophy, SHD = structural heart diseases, TA = thorax anomaly, VSD = ventricular septal defect.

### Table 3

| Types of SVT | SHD n=174 | NSHD n=1106 | P value | Total cohort n=1280 |
|--------------|-----------|-------------|---------|---------------------|
| AVNRT, %     | 42 (23.9) | 656 (58.0) | <.001   | 698 (53.4)          |
| AP, %        | 15 (8.5)  | 199 (17.6)  | .001    | 214 (16.4)          |
| AFL, %       | 108 (61.4)| 234 (20.7) | <.001   | 342 (26.2)          |
| AT, %        | 11 (6.2)  | 42 (3.7)    | .001    | 53 (4.0)            |
| PVCV, %      | 0 (0.0)   | 14 (1.3)    | –       | 14 (1.1)            |

AFL = atrial flutter and interatrial reentry tachycardia, AP = accessory pathways, AT = atrial tachycardia, AVNRT = atrioventricular nodal reentry tachycardia, NSHD = nonstructural heart disease, PVC = premature ventricular contractions, SHD = structural heart disease, SVT = supraventricular tachycardia, VT = ventricular tachycardia.
Casella et al.\cite{14} demonstrated that patients’ lifetime risks of cancer incidence and mortality from ZF procedures were reduced by 96% compared to those from conventional fluoroscopic procedures. Moreover, the genetic study revealed a substantial increase in the incidence of mutations associated with an increasing radiation dose.

The differences in clinical parameters might affect the prognosis after an ablative approach and these relationships were described by Sardu et al.\cite{25,26} Cardiac arrhythmias are a common occurrence after cardiac surgery because a new arrhythmogenic substrate appears, which is sometimes difficult to identify.\cite{33} Further, deformities of the spine move the heart inside the chest, resulting in an atypical anatomy of the heart in thoracic anomalies and advance scoliosis. This could be a real challenge for electrophysiologists. In this study, longer ablation time and parameters of CA were expected for SHD patients than those for patients with a normal heart anatomy; however, ZF were successfully and safely incorporated into daily practice in this group too.

Giaccardi et al.\cite{15} in their meta-analysis compared a group of 145 patients treated only under fluoroscopic guidance with 297 patients treated using a nonfluoroscopic electroanatomic mapping system (EnSite Velocity). They concluded that the conventional fluoroscopic technique and the near-zero radiation (RX) approach provide similar outcomes and may significantly reduce or eliminate ionizing radiation exposure in radiofrequency CA. Similar results were presented by Yang et al.\cite{15} although the results are mainly for patients without SHD.

Further, Mah et al.\cite{16} conducted a study in patients aged ≥10 years, weighing ≥35 kg, and having a normal cardiac anatomy or trivial structural heart defects such as bicuspid aortic valve or a persistent left superior vena cava. Patients were excluded if they had more than trivial congenital heart disease prior to ablation or prior to cardiac surgery. However, even with a combination of 3D-EAM and ICE, complete ZF approach was followed only in a minority of patients.\cite{17-30} In contrast, our study showed ZF approach feasibility wherein even in the SHD group, procedural time could be reduced significantly, probably because of lesser time spent on detailed contour mapping and multichamber 3D mapping.

In our study group, 174 individuals with SHD were compared with 1106 patients without SHD. In SHD the most frequent SVT is AFL, but in NSHD majority of SVTs are AVNRTs. We showed that SHD patients have worse exercise capacity and heart function than NSHD patients. Despite this, the ablation time was not longer and the number of applications was similar compared with those for NSHD patients.

Comparison of our previous data on implementation of ZF approach and current study shows encouraging constant value of ZF approach performance with very safe, effective, and fast procedures.\cite{13,31} There are, however, needs for new ZF dedicated catheters, selective use of ICE (for crossing aortic valve or need for transeptal puncture), CS catheter stability, and approach modification (patient preselection or magnetic resonance preprocedural imaging) to decrease number of cross-over to fluoroscopy.

### 4.1. Limitations

The present study had few limitations. Firstly, this is not randomized trial and not all severe SHD or GUCH were treated, but the study showed routine incorporation of ZF approach in regular conditions and practice of nonuniversity hospitals. Furthermore, the conversion to fluoroscopy could be decreased if the steerable decapolar catheter were used for CS cannulation. The learning curve of each individual or ZF approaches and EPS protocol could be different and had potential impact on procedural data. We did not make a detailed analysis of the clinical course in the studied groups while Sardu et al.\cite{12-14} showed that ventricular failure as a pump may result in worse results in patients with metabolic syndrome, diabetes mellitus, and other diseases that have been ablated. In our study, echocardiographic parameters were worse in the SHD group compared to NSHD. We did not study clinical differences or follow-up because we focused on assessing whether SHD patients are a more difficult group for ablation or not. The results showed that SHD patients are not an obstacle to ZF ablation. Finally, long-term follow-up should be performed (planned) to confirm the early encouraging results of this registry and cost-effectiveness. The results of this study and this ZF approach or its

| Table 4 | Electrophisiology study and ablation parameters. |
|---------|--------------------------------------------------|
|         | SHD n = 174                                      | NSHD n = 1106 | P value | Total cohort n = 1280 |
| Total procedure’s time, min | 51.2 ± 26.9 | 49.9 ± 25.2 | .55 | 50.0 ± 25.4 |
| Number of applications | 17.6 ± 13.2 | 20.2 ± 17.9 | .08 | 19.8 ± 17.5 |
| Time of applications, sec | 457.5 ± 356.3 | 360.2 ± 286.3 | <.001 | 380.5 ± 297.5 |
| Max Watt for applications, W | 50.4 ± 11.2 | 44.1 ± 11.1 | <.001 | 44.9 ± 11.3 |
| Max temp. of applications, °C | 58.4 ± 7.1 | 54.9 ± 7.4 | <.001 | 55.3 ± 7.4 |
| Power settings – Watt, W | 57.6 ± 928 | 52.0 ± 81.1 | <.001 | 52.7 ± 8.4 |
| Temperature settings, °C | 62.1 ± 4.1 | 60.1 ± 4.2 | <.001 | 60.4 ± 4.2 |
| ZF completed | n = 151 | n = 1019 | .02 | 1170 |
| Conversion to X-ray | (66.6%) | (92.1%) | (91.4%) |
| Time of X-ray in fluoroscopy group, min | 5.05 ± 5.13 | 5.59 ± 7.45 | .75 | 5.49 ± 7.08 |
| DAP, mGy × cm² | 1620.6 ± 2472.3 | 1152.4 ± 1650.1 | .48 | 1261.3 ± 1850.5 |
| Total number of applications | 17.6 ± 13.2 | 20.2 ± 17.9 | .08 | 19.8 ± 17.5 |
| Major complications, % | 1 (0.5) | 4 (0.4) | 5 (0.4) |

DAP = dose area, mGy = milligray, NSHD = nonstructural heart disease, SHD = structural heart disease.

Major complications: groin hematoma (n = 1) in SHD and AV fistula (n = 1), groin hematoma (n = 1) and pericardial effusion without tamponade (n = 2) in NSHD.
The minimally invasive ZF approach was successfully and safely implemented in majority of ablation procedures of regular SVT in SHD and NSHD patients although this method requires sufficient experience. Strict ZF approach even in patients with SHD should be routinely performed but additional imaging modalities or new devices dedicated for ZF procedures may decrease the rate of conversion to fluoroscopy and risk of complications and failures.

Conceptualization: Aleksandra Morka, Janusz Śledź, Sebastian Stec.

Data curation: Janusz Śledź, Karol Deutsch, Bartosz Ludwik, Sebastian Stec.

Formal analysis: Aleksandra Morka, Janusz Śledź, Magdalena Zagrodzka, Leslaw Szydłowski, Sebastian Stec.

Methodology: Aleksandra Morka, Janusz Śledź, Bartosz Ludwik, Magdalena Zagrodzka, Sebastian Stec.

Project administration: Aleksandra Morka, Janusz Śledź, Sebastian Stec.

Software: Janusz Śledź, Karol Deutsch, Bartosz Ludwik, Magdalena Zagrodzka, Sebastian Stec.

Validation: Janusz Śledź, Karol Deutsch, Bartosz Ludwik, Sebastian Stec.

Visualization: Aleksandra Morka, Janusz Śledź, Magdalena Zagrodzka, Sebastian Stec.

Writing – original draft: Aleksandra Morka, Leslaw Szydłowski, Sebastian Stec.

Writing – review & editing: Janusz Śledź, Bartosz Ludwik, Leslaw Szydłowski, Sebastian Stec.

References

[1] Page RL, Joglar JA, Caldwell MA, et al. Guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2016;133:e471–505.

[2] Blomstrom-Lundqvist C, Scheinman MM, Alot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology/Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003;108:1871–909.

[3] Lundqvist CB, Potpara TS, Malmborg H. Supraventricular arrhythmias in patients with adult congenital heart disease. Arrhythm Electrophysiol Rev 2017;6:42–9.

[4] Sánchez Y, Anvari A, Samir AE, et al. Navigational guidance and ablation planning tools for interventional radiology. Curr Probl Diagn Radiol 2017;46:225–33.

[5] Kovoor P, Ricciardello M, Collins L, et al. Radiation exposure to patient and operator during radiofrequency ablation for supraventricular tachycardia. Aust N Z J Med 1995;25:490–5.

[6] Sarkozy A, De Potter T, Heidbuchel H, et al. ESC Scientific Document Group. Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS). Europace 2017;19:1909–22.

[7] Matsu Y, Hiraki T, Gobara H, et al. Radiation exposure of interventional radiologists during computed tomography fluoroscopy-guided renal cryoablation and lung radiofrequency ablation: direct measurement in a clinical setting. Cardiovasc Intervent Radiol 2016;39:894–901.

[8] Buettner AE, Callins H, Callans DJ, et al. American College of Cardiology; American Heart Association Task Force on Clinical Data Standards; (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). J Am Coll Cardiol 2006;48:2360–96.

[9] Park T, Eichling J, Schechtman K, et al. Risk of radiation induced skin injuries from arrhythmia ablation procedures. Pacing Clin Electrophysiol 1996;19:1363–9.

[10] Needleman S, Powell M. Radiation hazards in pregnancy and methods of prevention. Best Pract Res Clin Obstet Gynaecol 2016;33:108–16.

[11] Chen G, Sun G, Xu R, et al. Zero-fluoroscopy catheter ablation of severe drug-resistant arrhythmia guided by Ensite NavX® system during pregnancy: Two case reports and literature review. Medicine (Baltimore) 2016;95:e4847.

[12] Kemmer CK, Maginot KR, Teelin T, et al. Complex 3D mapping in a young adult with D-TGA, atrial tachycardia and limited venous access: A case report. J Innov Card Rhythm Manag 2012;3:637–41.

[13] Stec S, Śledź J, Mazij M, et al. Feasibility of implementation of a “simplified, No-X-Ray, no-lead apron, two-catheter approach” for ablation of supraventricular arrhythmias in children and adults. J Cardiovasc Electrophysiol 2014;25:866–74.

[14] Casella M, Pelargonio G, Dello Russo A, et al. “Near-zero” fluoroscopic exposure in supraventricular arrhythmia ablation using the Ensite NavX™ mapping system: Personal experience and review of the literature. J Inter Card Electrophysiol 2011;31:109–18.

[15] Giacciardi M, Del Rosso A, Guarinacci V, et al. Near-zero x-ray in arrhythmia ablation using a 3-dimensional electroanatomic mapping system: A multicenter experience. Heart Rhythm 2016;13:150–6.

[16] Nah D, Miyake CY, Sherwin ED, et al. The use of an integrated electroanatomic mapping system and intracardiac echocardiography to reduce radiation exposure in children and young adults undergoing ablation of supraventricular tachycardia. Europace 2014;16:277–83.

[17] Gaita F, Guerra PG, Battaglia A, et al. The dream of near-zero X-rays ablation comes true. Eur Heart J 2016;37:2749–55.

[18] Yang L, Sun G, Chen X, et al. Meta-analysis of zero or near-zero fluoroscopy use during ablation of cardiac arrhythmias. Am J Cardiol 2016;118:1511–8.

[19] Razmnia M, Willoughby MC, Demo H, et al. Fluororeless catheter ablation of cardiac arrhythmias: A 5-year experience. Pacing Clin Electrophysiol 2017;40:425–33.

[20] Razmnia M, Manankil MF, Eryazici PL, et al. Nonfluoroscopic catheter ablation of cardiac arrhythmias in adults: Feasibility, safety, and efficacy. J Cardiovasc Electrophysiol 2012;23:1078–86.

[21] Brouwer C, Hazekamp MG, Zeppenfeld K. Anatomical substrates and ablation of reentrant atrial and ventricular tachycardias in repaired congenital heart disease. Arrhythm Electrophysiol Rev 2016;5:130–60.

[22] Casella M, Dello Russo A, Pelargonio G, et al. Near zero fluoroscopic exposure during catheter ablation of supRavenTrucl atrial arrhythmias: the NO-PARTY multicentre randomized trial. Europace 2016;18:1565–72.

[23] Real Zero Fluoroscopy Catheter Ablation. (ZERO-Fluoro) September 10, 2018; www.clinicaltrials.gov/NCT03458273.

[24] Zero-fluoroscopy Approach Versus Fluoroscopic Approach for the Ablation of Paroxysmal Supraventricular Tachycardia (ZFA-PSVT) February 6, 2017; www.clinicaltrials.gov/NCT03042078.

[25] Sardu C, Carreras G, Katsanos S, et al. Metabolic syndrome is associated with a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation. BMC Cardiovasc Disord 2014;4:176.

[26] Sardu C, Martella R, Testa G, et al. Electrophysiological mechanisms underlying the Inhibitory Cardiac syncope without asystolic significant pause: Therapeutic and prognostic implications. The ELICA randomized trial, Medicine (Baltimore) 2018;97:e11737.

[27] Karbarz D, Stec PJ, Deutsch K, et al. Zero-fluoroscopy catheter ablation of symptomatic premature atrial contractions from non-coronary cusp during pregnancy. Kardiol Pol 2017;75:1351.

[28] Deutsch K, Śledź J, Mazij M, et al. Maximum voltage gradient technique for optimization of ablation for typical atrial flutter with zero-fluoroscopic approach. Medicine (Baltimore) 2017;96:e6939.
[29] Miyake CY, Mah DY, Atallah J, et al. Nonfluoroscopic imaging systems reduce radiation exposure in children undergoing ablation of supraventricular tachycardia. Heart Rhythm 2011;8:519–25.

[30] Papagiannis J, Tsoutsinos A, Kirvassilis G, et al. Nonfluoroscopic catheter navigation for radiofrequency catheter ablation of supraventricular tachycardia in children. Pacing Clin Electrophysiol 2006;29:971–8.

[31] Stec S, Deutsch K, Zierczak-Krajka A. The world’s largest family with familial atrio-ventricular nodal reentry tachycardia. Kardiol Pol 2015;73:1339.

[32] Sardu C, Marfella R, Santamaria M, et al. Stretch, injury and inflammation markers evaluation to predict clinical outcomes after implantable cardioverter defibrillator therapy in heart failure patients with metabolic syndrome. Front Physiol 2018;9:758.

[33] Sardu C, Paolisso P, Sacca C, et al. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Cardiovasc Diabetol 2018;17:137.

[34] Sardu C, Santamaria M, Funaro S. Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome. Medicine (Baltimore) 2017;96:e6558.